Early Introduction of Cenobamate in Uncontrolled Focal Epilepsy: Insights from a Structured Controversy
Cenobamate represents a significant advancement in the treatment of drug-resistant focal epilepsy. Its early adoption in clinical practice has the potential to enhance patient outcomes. The expert panel provides recommendations that underscore individualized treatment planning, close monitoring during titration, and advocacy for improved accessibility. Continued research and policy initiatives are essential to fully realize the therapeutic potential of cenobamate.
Authors
- Elena Tartara (ORCID: https://orcid.org/0000-0003-1656-5420)
- Annacarmen Nilo (ORCID: https://orcid.org/0000-0001-9827-8059)
- Marta Piccioli (ORCID: https://orcid.org/0000-0002-7953-0906)
- Luigi Del Gaudio (ORCID: https://orcid.org/0000-0002-7413-3282)
- Gemma Tumminelli (ORCID: https://orcid.org/0000-0003-2098-5129)
- Angelo Labate (ORCID: https://orcid.org/0000-0002-8827-7324)
- Carlo Di Bonaventura (ORCID: https://orcid.org/0000-0003-1890-5409)
- Claudio Liguori (ORCID: https://orcid.org/0000-0003-2845-1332)
- Filippo Dainese
Institutions
- University of Messina (IT)
- University of Rome Tor Vergata (IT)
- University of Udine (IT)
- AOL (United States) (US)
- University of Padua (IT)
- Regione Campania (IT)
- Ospedale San Filippo Neri (IT)
- Policlinico Tor Vergata (IT)
- Sapienza University of Rome (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1007/s40120-025-00781-3
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Angelini Pharma